5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Innova Captab Ltd.

•
innovacaptab.comBSE: 544067NSE: INNOVACAP
Market Cap₹ 6,721 Cr.
Current Price
High / Low₹ 1,200 / 622
Stock P/E43.0
Book Value₹ 198
Price to Book3.61
Dividend Yield0.17 %
ROCE15.0 %
ROE13.7 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Drugs & Pharmaceutical Products: 100.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 32.5% CAGR over last 5 years
  • Company has consistently been profitable over the last 5 years
  • Latest quarter profit grew 42.3% YoY, showing strong momentum
  • Company has delivered good sales growth of 31.7% CAGR over last 5 years
  • Company comfortably covers its interest (12.1x coverage)
  • Company maintains a comfortable, low leverage position

CONS

  • Equity base is being diluted - shares outstanding up 19.2%
  • Valuation is stretched - P/E of 43.0 is well above its own 5-year median (27.9)
  • Though reporting repeated profits, the company pays out little dividend (8.1%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1899.0037.67455633.710.842901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9100.0082.59241576.410.33902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4850.0084.58184478.410.78566.003.284921.0057.3219.2733.81
4.CIPLA1385.0033.19111888.390.94785.55-39.187119.284.1316.0016.73
5.ZYDUSLIFE1121.0024.78111820.180.09990.20-34.908017.0023.9721.3924.54
6.LAURUSLABS1840.0090.9399417.450.11362.07123.942026.3129.1018.2031.50
7.LUPIN2111.0017.4696528.820.851416.9816.018276.8934.2828.8629.59
8.DRREDDY1154.0029.8996322.060.69435.60-69.108099.80-5.2113.7510.63
9.MANKIND2328.5547.0996179.610.04574.0929.124030.5912.8913.2426.30
10.AUROPHARMA1653.3025.6295127.230.241032.0325.229150.3517.4412.7620.54
11.GLENMARK2427.0038.1068495.930.10482.83927.884018.4831.3520.3520.03
12.INNOVACAP1174.4543.006720.780.1744.1342.27470.8533.9415.0415.53
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
233283302263294318316315352380450448471
202242258225252268270267299329381399414
Operating Profit31404538425047485252694957
OPM %13.42%14.30%14.74%14.50%14.33%15.63%14.71%15.15%14.82%13.63%15.41%10.97%12.10%
1326224344222
Interest5971000236454
Depreciation3553555101111111112
Profit before Tax25303540394746394339565159
Tax %28.50%24.12%28.64%27.36%25.01%25.23%24.96%24.78%27.32%24.39%24.30%20.38%25.19%
Net Profit0000293534303130424044
3.674.774.395.025.156.125.975.175.425.187.377.057.71

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
3563734118019261,0811,2441,6301,749
3153223567058139271,0581,3981,522
Operating Profit41515496114154186232227
OPM %11.46%13.64%13.27%11.99%12.27%14.28%14.97%14.21%13.00%
011391212199
Interest6546202121718
Depreciation1110681116254546
Profit before Tax2538468692130171188205
Tax %19.74%25.70%25.56%25.39%25.97%27.16%25.00%25.15%23.60%
Net Profit202834646894128141156
EPS4.145.817.1913.3214.1616.4922.4124.63—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%8.12%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
32%
3 Years:
21%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
33%
3 Years:
28%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
28%

RETURN ON EQUITY

10 Years:
—
5 Years:
22%
3 Years:
15%
Last Year:
14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Jan 30

₹ 0.20

Interim Dividend

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital1212121248575757
70981331972297749021,034
725446199245234311315
Trade Payables6272112145158180202319
1218102606985120134
Total Liabilities2282544046127481,3291,5921,858
787379183183358830842
Capital Work in Progress0070223412316
000000041
396591128117144208283
00000288332437
Cash & Bank251221987684
109110215298408111131235
Total Assets2282544046127481,3291,5921,858

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
284055808714664117
Cash from Investing-9-6-20-188-91-499-152-107
Cash from Financing-9-23-191252736192-22
113-5384-12

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
PER SHARE
EPS (₹)166.01232.22286.86531.5414.1616.4922.4124.63
Book Value (₹)687.39919.621206.841738.3857.61145.20167.66190.61
Dividend per Share (₹)0.000.000.000.000.000.000.002.00
Cash EPS (₹)6.367.918.3514.8916.4619.2826.7432.52
PROFITABILITY
Operating Margin %11.52%13.96%13.57%12.23%13.07%14.25%14.71%13.96%
Net Margin %5.58%7.46%8.38%7.91%7.23%8.71%10.13%8.49%
ROE %24.10%28.92%27.04%36.19%28.02%17.04%14.33%13.75%
ROCE %19.63%26.48%28.42%30.64%24.34%19.06%14.65%15.04%
8.72%11.57%10.48%12.58%9.99%9.08%8.78%8.17%
EFFICIENCY
Debtor Days93871007993938985
Inventory Days4051705048445154
Payable Days10110912389100107109115
3129474040313124
FINANCIAL HEALTH
Debt to Equity (x)0.87x0.48x0.31x0.95x0.85x0.29x0.35x0.31x
Interest Coverage (x)5.44x9.11x12.80x16.09x5.60x7.04x72.11x12.14x
1.26x1.39x1.26x1.27x1.59x2.07x1.91x1.83x
GROWTH
Revenue Growth %0.00%4.92%10.00%94.94%15.72%16.72%15.02%31.06%
Operating Profit Growth %0.00%27.37%6.94%77.06%24.21%35.90%18.72%26.31%
Net Profit Growth %0.00%40.30%23.72%85.37%6.26%38.84%35.95%9.87%
0.00%0.00%0.00%0.00%0.00%16.46%35.95%9.87%
VALUATION
P/E (x)0.00x0.00x0.00x0.00x0.00x27.18x39.15x27.91x
P/B (x)0.00x0.00x0.00x0.00x0.00x3.09x5.23x3.61x
Dividend Yield %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.29%
0.00x0.00x0.00x0.00x0.00x16.29x26.69x17.07x

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
50.9050.9050.9050.9050.9050.9050.9050.90
1.010.740.350.230.070.100.230.34
20.6119.9619.7719.6720.1720.2420.1419.92
Government0.000.000.000.000.000.000.000.00
27.4828.4128.9929.2028.8528.7628.7328.84

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-05
Copy of Newspaper Publication

2026-09-05 - Innova Captab Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-05
General Updates

2026-09-05 - Innova Captab Limited has informed the Exchange about General Updates

2026-09-04
Shareholders meeting

2026-09-04 - Innova Captab Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026

2026-09-03
Copy of Newspaper Publication

2026-09-03 - Innova Captab Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-03
Outcome of Board Meeting

2026-09-03 - Innova Captab Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.

2026-08-23
Copy of Newspaper Publication

2026-08-23 - Innova Captab Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-22
General Updates

2026-08-22 - Pursuant to regulation 30 (read with part A of schedule III) and other applicable provisions ofSEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations )and with reference to the our letter dated 24th June, 2026 regarding postponement of22nd Annual General Meeting ( AGM ) of the Company and in continuation of intimation ofoutcome of the Board meeting of the Directors commenced on Friday, 21st August, 2026 at23:16 hours (IST) and concluded on Saturday, 22nd August, 2026 at 00:25 hours (IST), we wish toinform you that the Board of Directors has also approved the notice for calling 22nd AnnualGeneral Meeting ( AGM ) of the Company for the financial year 31st March, 2026. The 22nd AGMNotice along with the annual report will be submitted to the stock exchange(s) in due course oftime.

2026-08-22
Capacity addition

2026-08-22 - Innova Captab Limited has informed the Exchange about Capacity addition

2026-08-22
Outcome of Board Meeting

2026-08-22 - Innova Captab Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

News

Recent coverage and analyst commentary for INNOVACAP

Loading news…

🤖

AI Stock Analyst

Innova Captab Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login